Monitor the upcoming general meeting proxy statement for any additional governance or strategic updates. This filing does not alter the company's fundamental distress — focus on the Nasdaq delisting resolution and cash runway from the Psyga Bio acquisition.
Price Chart
Executive Summary
XTL Biopharmaceuticals filed a 6-K reporting the resignation of external director Iris Shapira Yalon for personal reasons, effective by November 20, 2026, and the nomination of Gilai Dolev as her replacement, subject to shareholder approval. This is a routine board change with no material financial or operational impact, but it occurs against the backdrop of the company's severe financial distress (going-concern opinion, $76k cash, Nasdaq delisting risk) and the recent Psyga Bio acquisition.
Key Facts
- Iris Shapira Yalon resigned from the Board of Directors on October 12, 2026, effective upon appointment of successor or November 20, 2026.
- Resignation is for personal reasons, not due to any disagreement with the company.
- Board nominated Gilai Dolev for election as external director for a three-year term, subject to shareholder approval.
- Company will convene a general meeting to approve the nomination and will file the proxy statement on Form 6-K.
Financial Impact
No financial impact — routine board change with no disclosed financial terms.
Risk Factors
- Board change is routine but occurs during a period of severe financial distress and Nasdaq non-compliance.
- No material impact on operations or financial outlook.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-109415 |
| Document: 0001213900-26-109415-index-headers.html | 0001213900-26-109415 |
| Document: 0001213900-26-109415-index.html | 0001213900-26-109415 |
| Document: 0001213900-26-109415.txt | 0001213900-26-109415 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 6-K | $1.91 | awaiting T+60 | — | $1.82 (−4.71%) |
Jun 30, 2026 16w ago | 20-F | $2.49 $2.41 | ▲ +3.21% | ▲ +6.08% | $1.82 (+26.91%) |
Jun 29, 2026 17w ago | 6-K | $2.73 $2.20 | ▼ −19.41% | ▼ −22.23% | $1.82 (−33.33%) |
May 22, 2026 22w ago | 6-K | $2.38 $2.98 | ▼ −25.21% | ▼ −22.49% | $1.82 (+23.53%) |
May 7, 2026 24w ago | 6-K | $2.67 $2.86 | ▲ +7.15% | ▲ +3.31% | $1.82 (−31.84%) |
Apr 29, 2026 25w ago | 6-K | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.82 (−48.88%) |
Apr 29, 2026 25w ago | Press Release | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.82 (−48.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers